Tempus swung to adjusted profit, sales rose, and it expects $192.5 million from new data deals over about 5 years. Hereditary testing sales grew 3%, but oncology testing volume and data and applications sales also grew.
Cancer testing volume and sales from data products both grew, and the new agreements give Tempus another source of sales over about 5 years. The agreements are expected to bring in $192.5 million. Hereditary testing sales grew 3%, but oncology testing volume and data and applications sales also grew.
Bristol Myers is licensing Tempus oncology data and joining an Alzheimer’s data project. The story gives no expected change to Bristol Myers’ sales or costs overall.
Follow Tempus AI Inc. (TEM) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for TEM